Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07190859

Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic

This is a double-blind, randomized, placebo-controlled, parallel-group study in infants with colic with the primary objective to evaluate crying and fussing time.

Recruiting

Interested in participating?

Request Info

Key information

Age range

3 week–12 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UMHAT Deva Maria, Burgas, Bulgaria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 3-12 weeks at screening.
  • Gestational age 37+0 weeks - 42+0 weeks at birth.
  • Birth weight appropriate for gestational age (AGA - weight between 10th and 90th percentile) or Large for Gestational Age (LGA - weight above the 90th percentile) determined using WHO Weight-for Age percentile guides.
  • Parents/caregivers/legal guardians are >18 years.
  • Exclusively or predominantly breastfed infants (> 50 % breast fed).
  • Willing to maintain current feeding patterns (not change formula/not change ratio of formula:breast milk etc.).
  • Readiness and the opportunity for parents/caregivers/legal guardians to fill out a study diary, questionnaires.
  • Infantile colic diagnosed according to Rome IV criteria (face-to-face consult with a physician, parents/caregivers/legal guardians must report that their infant has cried or fussed for 3 or more hours per day, during 3 or more days in the preceding week). At Visit 2, this will be confirmed by Baby's Day Diary®, at least one 24-hour period should show 3 or more hours of crying/fussing time.
  • Parents/caregivers/legal guardians with ability to understand and comply with the requirements of the study, as judged by the Investigator.
  • Parents/caregivers/legal guardians willing and able to give informed consent for their and their infant's participation in the study.
  • The mother of the infant must be willing to attend Visit 2 (Day 0), Visit 3 (Day 8), and Visit 4 (Day 22).
  • Infant is considered healthy, in the opinion of the investigator following physical exam.

Exclusion criteria

  • Infants with severe gastroesophageal reflux (throwing up or spitting up more than a teaspoon of milk > 8 times daily, projectile, bilious or bloody emesis).
  • Infants with failure to thrive, intrauterine growth retardation, haematochezia (blood in the stools), diarrhoea (watery stools that takes the shape of a container > 12x in breastfed and >5 in partially breastfed infants daily), or fever (38.0 degrees), as reported by parents/caregivers/ legal guardians.
  • Infants with congenital heart disease, immunodeficiency, asplenia, cancer, cystic fibrosis, and those with liver disease.
  • Infants with reported exposure to probiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.
  • Infants with reported exposure to oral and/or systemic antibiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.
  • Infants with reported exposure to medications, therapies, or products with the aim to relieve infantile colic including proton pump inhibitors in the 7 days prior to Screening Visit (V1) and throughout the study period.

Treatment and study plan

L. reuteri

Dietary Supplement

Supplementation with drops containing L. reuteri once daily for 21 consecutive days

Placebo

Dietary Supplement

Supplementation with identical drops without L. reuteri once daily for 21 consecutive days

Primary outcomes

  1. Crying and fussing time

    Time frame: From baseline to Day 7

    Change in mean crying and fussing time as assessed by the Baby's Day Diary

Secondary outcomes

  1. Crying and fussing time

    Time frame: From baseline up to Day 21

    Change in mean crying and fussing time as assessed by the Baby's Day Diary

  2. Number of responders

    Time frame: From baseline up to Day 21

    Proportion of responders defined as reduction of daily average crying time with 50 % compared to baseline

  3. Family Quality of Life

    Time frame: From baseline up to Day 21

    Change in family QoL measured by the PedsQL Family Impact Module (Acute) - Total Score

  4. Sleeping time

    Time frame: From baseline up to Day 21

    Change in mean sleeping time as assessed by Baby´s Day Diary

  5. Maternal depression

    Time frame: From baseline up to Day 21

    Change in maternal depression as assessed by the Edinburgh Postnatal Depression Scale Total Score

Study contacts

Contact information is provided by the study sponsor or research team.

Petra J Lierud

CONTACT

[email protected]

+46724504400

Sanna Nyström, PhD

CONTACT

[email protected]

+46761483866

Sponsors and collaborators

Lead sponsor

BioGaia AB

Industry

Registry information

Official study title

A Double-blind, Randomised, Placebo-controlled, Parallel-group Study Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 24, 2025
Registry last updated
Sep 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.